DailyIQ
Last updatedjust now

PODD·Insulet Corporation

$134.85
+0.12 (+0.09%)
High
$137.10
Open
$134.99
Market Cap
9.41B
52W High
$361.24
Low
$133.33
P. Close
$134.85
P/E
25.06
52W Low
$126.40
Fwd P/E
17.59
DailyIQ Est.
$180.83
Inst. Ownership
53.8%
Short Interest
7.35%
Days to Cover
3.1
Technical Score (1D)
18
BEARISH
News Sentiment
58
BULLISH
On Oct 7, Barclays analyst Christopher Pasquale initiated coverage on Insulet (NASDAQ:PODD) with an equal‑weight rating and a price target of $150. The analyst’s move signaled a bullish view on the company’s prospects, reflecting confidence in its product pipeline and market positioning. The coverage launch was reported to potentially boost investor interest and trading volume. No earnings or operational updates were disclosed in the announcement. The rating positioned Insulet favorably among peers in the diabetes care sector.
LOW TARGET
$144 +6.8%
3 analysts
MEAN TARGET
$172 +27.5%
10 analysts
HIGH TARGET
$275 +103.9%
22 analysts
PRICE RANGE
$144.00 - $275.00
SB / B / H / S / SS
9/11/13/1/1
DAILYIQ EST.
$180.83 (+34.1%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NMS
Country
United States
Symbol
PODD
Description
Insulet Corporation is a medical device company specializing in insulin delivery systems for individuals managing insulin-dependent diabetes. Its core offering is the Omnipod platform, featuring the Omnipod 5, an automated insulin delivery system that integrates with continuous glucose monitors for real-time glucose monitoring and insulin adjustments. The company also offers the Omnipod DASH system, a user-friendly insulin management system controlled via a smartphone-like device. Furthermore, Insulet manufactures pods for Amgen's Neulasta Onpro kit, a delivery system designed to mitigate infection risks for chemotherapy patients. Insulet distributes its products through pharmacies and independent distributors, providing a comprehensive solution for insulin delivery.
Bought (1Y)
7,340 shares
$1.1M
Sold (1Y)
3,955 shares
$556K
Pease FlaviaEVP & CFO
Tax Withholding1,882 shares2026-10-01
Huffines Robert Luther-
Award/Grant178 shares2026-09-30
MAZELSKY JONATHAN JAY-
Award/Grant141 shares2026-09-30
McEvoy AshleyPresident and CEO
Buy1,100 shares2026-08-21
Davis Lisa BlairSVP, Chief HR Officer
Tax Withholding244 shares2026-08-01
83/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
71.6%
Net Margin
9.1%
Revenue CAGR
26.1%
Current Ratio
2.81x
Debt / Equity
0.63x
Return on Equity
16.3%
Earnings Summary
Insulet Corporation, a medical device firm focused on insulin delivery systems such as the Omnipod 5 and Omnipod DASH, operates within the healthcare sector’s medical devices niche, serving diabetes patients and chemotherapy patients through its pod technologies. In the most recent quarters, Insulet posted EPS of $1.15 in Q4 2024 and $1.02 in Q1 2025, both beating estimates of $1.02 and $0.79 respectively, while revenue rose to $597.5 M and $569 M, indicating a modest revenue decline but strong profitability. The following quarters saw EPS climb to $1.17 in Q2 2025 and $1.24 in Q3 2025, with revenue increasing to $649.1 M and $706.3 M, respectively, reflecting accelerating earnings growth and a rebound in top line momentum. In Q4 2025, EPS surged to $1.55 against an estimate of $1.18, and revenue hit $783.8 M versus an estimate of $714.3 M, marking the strongest quarterly performance in the dataset. Historically, Insulet has shown a consistent upward trajectory in EPS, with each quarter beating analyst expectations and revenue growth outpacing EPS in earlier periods, underscoring a robust earnings expansion despite occasional revenue dips. Recent news highlights a forthcoming Q3 2026 earnings call announced on October 1, 2026, and analyst commentary on potential headwinds from new entrants and price pressure in 2027‑28, suggesting that while current performance is solid, competitive dynamics may influence future margins.

EPS

EstBeatMiss
$0.81$1.05$1.29$1.53$1.77Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.59 - -
Q2'26$1.48$1.66+12.2%
Q1'26$1.19$1.42+19.3%
Q4'25$1.18$1.55+31.5%
Q3'25$1.15$1.24+8.1%
Q2'25$0.92$1.17+26.8%

Revenue

EstBeatMiss
$619M$684M$750M$815M$880MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$850M - -
Q2'26$803M$802M-0.2%
Q1'26$730M$762M+4.3%
Q4'25$714M$784M+9.7%
Q3'25 - $706M -
Q2'25 - $649M -

Market Data

PODD Stock Snapshot

BEARISH18/100
$134.85+$0.12 (0.1%)
Market cap
9.41B
P/E ratio
25.1
Day range
$133.33 – $137.10
News sentiment
58/100 · Neutral
Analyst target
$171.91 (+27.5%)
Consensus
Hold · 35 analysts
52-week range+6.7% off low · -62.7% from high
$126.40$361.24
Price $134.85 DailyIQ Est. $180.83

PODD is on the weaker side of its setup, with little confirmation for a reversal yet. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Reverse DCF

What growth is priced into PODD?

CHEAP

At today's price, Insulet Corporation needs to grow free cash flow about 12.9% a year for the next 10 years to justify its valuation at a 8.59% cost of capital. Over its actual history it has compounded free cash flow at 132.1% a year, so the market is asking for 119.3 percentage points below its own delivered rate. On that basis PODD looks priced below what its own growth record supports.

Implied FCF growth
12.9%
Historical FCF CAGR
132.1%
Growth gap
-119.3 pts
Verdict
CHEAP
Discount rate (WACC)
8.59%
Beta
0.74

Behaviour On Record

What PODD's own history says about today's numbers

Realized volatility (21d)
32.0% 38th pct
Below its peak
-61.6%
vs 200-day average
-29.9%
Up days (1y)
48%

Insulet Corporation is currently running 32.0% annualised volatility over the last 21 sessions. Measured against PODD's own 13 years of daily returns rather than a market-wide average, that is the 38th percentile — on the quiet side for this stock, against a typical reading of 36.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

PODD is trading -61.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -32.7%, and the deepest was -61.3% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -29.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 6th percentile — a narrower gap than it typically runs. Over the past year PODD closed higher on 48% of sessions, and it is currently 3 sessions into a rising streak.

On October specifically: over 13 years of records, PODD finished the month higher 7 of 13 times, with a median return of +2.3% and an average of -0.1%. Its strongest month historically has been November at +10.6% on average, its weakest September at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: PODD has opened more than 2% away from the prior close in 165 of 3,267 sessions (5.1% of the time), with the largest gaps running +16.4% and -12.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, PODD moved an average of 4.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +5.3% and a largest of +6.0%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against PODD's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of PODD's sector?

Insulet Corporation sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Medical Devices industry group, PODD ranks 3rd of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
73
Industry rank
#3 of 15

Options Market

What is the options market pricing for PODD?

CallsPuts

For Insulet Corporation's nearest expiry (2026-10-16, 9 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.76), with at-the-money implied volatility around 42.7%. The options market is pricing roughly a ±6.6% move by that expiry — a range of about $127.13–$144.97.

Put/call ratio (2026-10-16)
0.76
ATM implied volatility
42.7%
Total open interest
2,990
Expected move by 2026-10-16
±6.6% ($127.13–$144.97)

Analyst Rating Changes

Are analysts turning bullish or bearish on PODD?

Barclays most recently initiated coverage on Insulet Corporation to Equal-Weight on Oct 7, 2026 with a price target of $150. Over the last 90 days, coverage has run 0 upgrades against 5 downgrades, a net bearish lean.

Latest action
Barclays — Equal-Weight
90-day upgrades
0
90-day downgrades
5
Net rating momentum
-5
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedEqual-Weight$150
Aug 6, 2026Canaccord GenuityMaintainedBuy$249 → $179
Aug 6, 2026Leerink PartnersDowngradeOutperform → Market Perform$247 → $145
Aug 6, 2026TD CowenMaintainedHold$294 → $144
Aug 6, 2026UBSMaintainedNeutral$174 → $150
Aug 6, 2026RBC CapitalMaintainedOutperform$245 → $160
Aug 6, 2026BernsteinMaintainedOutperform$200 → $175
Aug 6, 2026BenchmarkMaintainedBuy$250 → $185
Aug 6, 2026StifelMaintainedBuy$225 → $180
Aug 6, 2026Wells FargoDowngradeOverweight → Equal-Weight$255 → $144
Aug 6, 2026JP MorganDowngradeOverweight → Neutral$275 → $152
Aug 6, 2026BTIGDowngradeBuy → Neutral-

PODD Competitive Positioning

Insulet Corporation (PODD) is tracked alongside these names in Medical Devices on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

58/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Barclays analyst Christopher Pasquale opened coverage on Insulet (NASDAQ:PODD) with an equal‑weight rating and a $150 price target. The move signals a bullish view on the company’s prospects, suggesting confidence in its product pipeline and market positioning. The coverage initiation may influence investor sentiment and could lead to increased trading activity. No immediate earnings or operational updates were disclosed, but the rating reflects a positive outlook on future growth. The announcement positions Insulet favorably among peers in the diabetes care sector.
What did this article say?
Insulet Corporation announced that it will report its third‑quarter 2026 financial results on November 4, 2026, ahead of market opening. The company will host a conference call at 8:00 a.m. Eastern Time to discuss the results. Investors can access the call live or via replay on Insulet’s Investor Relations website. No earnings guidance or performance data were disclosed in the announcement. The update simply informs stakeholders of the upcoming earnings release date.
What did this article say?
Insulet (PODD) demonstrated robust growth and profitability metrics while maintaining a valuation considered reasonable compared to its peers. The company’s financial performance suggests a solid foundation for continued expansion. Analysts view the stock as an appealing option for investors seeking affordable growth exposure within the medical device sector.
What did this article say?
Insulet (PODD) identified emerging headwinds from new market entrants in 2027 and 2028. Analysts noted rising price pressure, with 10‑20% of the commercial user base potentially exposed to managed Medicaid or non‑preferred pricing. The company may negotiate additional rebate concessions of 5‑10% for 2027. Intellectual property moat is limited to one‑piece architecture, with two‑piece coverage expired. Oppenheimer maintained a perform rating.
What did this article say?
Insulet’s stock fell 57.2% over the past year, prompting analysts to question whether the current market price is justified by the company’s projected cash flows. The firm’s valuation hinges on its ongoing device and consumable sales, which drive revenue conversion into cash. A discounted‑cash‑flow model suggests the shares may be trading below intrinsic value, highlighting potential undervaluation amid declining share performance.
What did this article say?
Insulet (PODD) completed a refinancing that swapped $475 million of term loans for lower‑interest debt and expanded its revolving credit facility, improving its balance sheet. The move came after the stock had fallen 52 % year‑to‑date and a 58 % decline in total shareholder return, indicating waning investor enthusiasm. While the debt restructuring reduces interest expense, it does not address the broader loss of momentum or the recent index removal, leaving the upside limited.
What did this article say?
Insulet’s Chief Operating Officer highlighted the company’s expansion of automated insulin delivery (AID) systems to 26 countries, including 20 markets with Omnipod 5. The firm plans to add more customers this year than it had in total during the decade prior to the COO’s tenure. With less than half of the 1.8 million U.S. Type 1 diabetes patients using AID and about 5% of 2.5 million insulin‑intensive Type 2 patients using the technology, Insulet is positioning itself to capture a larger share of the market.
What did this article say?
Insulet Corporation presented at the Bernstein Insights 3rd Annual Healthcare Leaders and Disruptors Forum on September 24, 2026. The company highlighted its latest product developments and strategic initiatives aimed at expanding its market presence. The presentation focused on technological advancements and regulatory milestones, but did not announce any new financial guidance or material corporate actions. The event was positioned as a routine industry engagement without immediate implications for investors.
What did this article say?
Insulet Corporation (NASDAQ: PODD) will present its latest developments at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 24, 2026. The company’s participation signals ongoing engagement with industry leaders and a commitment to showcasing its Omnipod product platform. While the event is a routine marketing activity, it may provide insights into future product roadmaps and strategic priorities.
What did this article say?
Insulet Corporation (PODD) participated in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, where CEO Ashley McEvoy and other executives outlined the company’s ongoing product development and market expansion plans. The presentation focused on incremental updates to the Omnipod insulin delivery system and discussed potential regulatory milestones for upcoming product iterations. No new financial guidance, contracts, or material risks were disclosed, indicating a routine update rather than a catalyst for price movement.

Technical Analysis

Real-time indicators across multiple timeframes

18
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.68B combined position · 13 adding, 10 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell8,701,47212.58%$2.47B2026-01-29
BlackRock, Inc.▲ Buy6,690,1929.67%$1.02B2026-08-07
AQR Capital Management LLC▲ Buy2,455,1353.55%$373.79M2026-08-14
Baillie Gifford & Co▲ Buy2,042,3132.95%$310.94M2026-08-06
Geode Capital Management, LLC▼ Sell2,003,8612.90%$303.97M2026-08-12
Two Sigma Investments, LP▲ Buy1,903,7342.75%$289.84M2026-08-14
Invesco Ltd.▲ Buy1,694,6512.45%$258.01M2026-08-14
Morgan Stanley▲ Buy1,479,0502.14%$225.19M2026-08-13
Norges Bank▼ Sell1,047,9861.51%$159.56M2026-08-12
FMR LLC (Fidelity)▼ Sell964,2971.39%$146.81M2026-08-13
Millennium Management LLC▲ Buy865,3871.25%$131.76M2026-08-14
Citadel Advisors LLC• Hold861,7461.25%$131.20M2026-09-02
Marshall Wace, LLP▲ Buy606,4820.88%$127.26M2026-05-15
Goldman Sachs Group Inc▼ Sell818,2651.18%$124.58M2026-08-14
Northern Trust Corp▼ Sell649,9080.94%$98.95M2026-08-13
JPMorgan Chase & Co▲ Buy595,1230.86%$94.39M2026-08-12
Man Group plc▼ Sell517,2170.75%$78.75M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy448,3200.65%$68.26M2026-08-14
Bank of America Corp▲ Buy426,4090.62%$64.92M2026-08-14
Squarepoint Ops LLC▲ Buy281,2420.41%$42.82M2026-08-14
Artisan Partners Limited Partnership▼ Sell260,2450.38%$39.62M2026-08-13
Renaissance Technologies LLC▼ Sell202,0830.29%$30.77M2026-08-13
Janus Henderson Group plc• Hold144,8180.21%$30.39M2026-05-18
William Blair Investment Management, LLC▼ Sell139,1300.20%$29.20M2026-05-08
Capital World Investors▲ Buy172,7120.25%$26.30M2026-08-12
Q2 2026 flow:4.74M sh bought ($723.71M)3.99M sh sold ($607.15M)net +752.7K sh (+$116.56M)
Congressional Trading Activity
8 disclosed trades · ~$1.19M est. traded value · 1 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-08-182026-09-10
Tina SmithSenateMN▼ Sell$100K - $250K2026-05-072026-05-10
Tina SmithSenateMN▼ Sell$100K - $250K2026-04-292026-05-10
Tina SmithSenateMN▼ Sell$50K - $100K2024-04-042024-04-19
Tina SmithSenateMN▼ Sell$250K - $500K2020-03-172020-04-16
Tina SmithSenateMN▼ Sell$15K - $50K2018-08-302018-09-19
Tina SmithSenateMN▼ Sell$100K - $250K2018-06-012018-06-11
Tina SmithSenateMN▼ Sell$100K - $250K2018-03-022018-03-06